| P50 | author | Paul Oberstein | Q57885707 |
| | Lei Zheng | Q59833013 |
| | Michael Goggins | Q63021511 |
| | Mark Yarchoan | Q85494951 |
| | Elizabeth Jaffee | Q29452184 |
| P2093 | author name string | Dung T Le | |
| | Ross C Donehower | |
| | Robert L Fine | |
| | Nilofer S Azad | |
| | Daniel A Laheru | |
| | Ana De Jesus-Acosta | |
| | Burles A Johnson | |
| | Melinda C Myzak | |
| P2860 | cites work | Fanconi anemia gene mutations in young-onset pancreatic cancer | Q73400804 |
| | High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 |
| | Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene | Q24658271 |
| | Management of borderline resectable pancreatic cancer | Q26781445 |
| | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 |
| | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Cancer statistics, 2016 | Q29547383 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 |
| | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 |
| | Pancreatic cancer | Q29622871 |
| | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 |
| | A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. | Q33161027 |
| | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Q33435836 |
| | Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen | Q36646204 |
| | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. | Q36740692 |
| | BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma | Q36854437 |
| | A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 |
| | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | Q38387666 |
| | FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy | Q38549680 |
| | Genomic analyses identify molecular subtypes of pancreatic cancer | Q38791499 |
| | Cancer treatment and survivorship statistics, 2016. | Q38859236 |
| | Cisplatin resistance associated with PARP hyperactivation | Q43703967 |
| | Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. | Q44049901 |
| | Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial | Q47440559 |
| | Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma | Q50852180 |
| | Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. | Q53649002 |
| | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 |
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | olaparib | Q7083106 |
| | irinotecan | Q412197 |
| P304 | page(s) | 44073-44081 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer | |
| P478 | volume | 8 | |